Foghorn Therapeutics (FHTX) Short term Debt (2019 - 2020)
Foghorn Therapeutics' quarterly Short term Debt came in at $6.0 million in Q3 2020, up 44.27% quarter-over-quarter from $4.2 million in Q4 2019.
Foghorn Therapeutics has reported Short term Debt for 2 years, with the latest figure at $6.0 million in Q3 2020.
- For the quarter ending Q3 2020, Short term Debt changed N/A year-over-year to $6.0 million; the trailing twelve-month figure through Sep 2020 stood at $6.0 million (changed N/A YoY), and the FY2019 full-year result was $4.2 million, changed N/A from the prior year.
- Short term Debt for Q3 2020 stood at $6.0 million, up from $4.2 million in the prior quarter.
- The five-year high for Short term Debt was $6.0 million in Q3 2020, with the low at $4.2 million in Q4 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Foghorn Therapeutics | 297.63 Mn | 208.72 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 5.99 Mn |
| Dec 31, 2019 | 4.15 Mn |